University Medical Centre Utrecht (Netherlands) ^{Research Centre}

REMAP-CAP is a randomised controlled trial for patients admitted to the intensive care unit (ICU) with severe Community-Acquired Pneumonia (CAP). All patients with severe CAP who are treated in an ICU will receive a combination of multiple different treatments. For many of these treatments, different options are available and used variably in current standard practice. An example of one of these treatments is antibiotics to treat infection. There are a number of different antibiotics that are widely used for patients with CAP, which are known safe and effective but it is not currently known which one is best. This trial studies a number of different treatment categories under one platform with an aim to determine the best package of treatment for patients. In addition to testing different treatment categories, the trial will also be 'adaptive'. In REMAP-CAP data will be reviewed regularly and dependent upon the results, the trial will allocate more patients to the treatments that seem to be the most beneficial. Each research site will also be able to choose which interventions to make available at that site, from among those available within the trial. REMAP-CAP will take place in 20 hospitals within the UK and aims to enrol 800 patients. The primary objective is to identify the most clinically effective treatments for adult ICU patients with severe CAP. The eligibility criteria for patients are applied at two levels. The first level is the patient eligibility to the overall trial. Once the patient meets these criteria, they can then be reviewed for eligibility to specific treatment categories. Patients will be followed up to 6 months after enrolment. This important and high quality trial will allow us to determine the best range of treatments for treating community acquired pneumonia on a global scale.